



## MediWound to Present at Upcoming Investor Conferences

February 17, 2026

### MediWound to Present at Upcoming Investor Conferences

**YAVNE, Israel, February 2026 ,17** -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences:

#### Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Time: 10:40 a.m. ET

Location: Virtual

Webcast: [Available via conference website](#)

#### TD Cowen 46th Annual Health Care Conference

Date: Monday, March 2, 2026

Time: 1:10 p.m. ET

Location: Boston Marriott Copley Place, Boston, MA

Webcast: [Available via conference website](#)

A live webcast and replay of each presentation will be accessible through the [Events & Presentations](#) section of the Investor Relations area of MediWound's website.

#### About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company's FDA-approved biologic, NexoBrid<sup>®</sup>, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound's late-stage pipeline product, EscharEx<sup>®</sup>, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit [www.mediwound.com](http://www.mediwound.com) and follow us on [LinkedIn](#) and [X \(formerly Twitter\)](#).

#### MediWound Contacts:

Hani Luxenburg  
Chief Financial Officer  
MediWound Ltd.  
[ir@mediwound.com](mailto:ir@mediwound.com)

Daniel Ferry  
Managing Director  
LifeSci Advisors, LLC  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)